Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,173.00+0.74%ETH$2,416.48+0.77%GOLD$4,313.30-1.69%OIL$101.66-0.75%
Smart Investors Daily
QL

NASDAQ · QLGN

Qualigen Therapeutics, Inc.

Healthcare · Biotechnology

$3.21

Up+$0.17 (+5.59%)

Updated Sep 17, 2026, 12:03 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.43M
P/E ratio
-0.22
Dividend yield
0.00%
52-week range
$1.61 – $8.81
Volume
373.84K
Avg. volume
2.65M

Price performance

QLGN price history

1M range · 0 trading sessions · Daily adjusted prices

QLGN does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest QLGN news

The latest Smart Investors Daily articles mentioning QLGN.

Stock researchCompany · Overview

QLGN research

Overview

Company profile and research snapshot.

Company profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 9, 2025

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Early as this Month

Faraday Future plans to enter pilot build and production phase for FX Super One, with first parts shipment scheduled for November 15, 2025. The company filed a blockchain-based car sharing patent and is preparing to release Q3 2025 financial results.

defenseworld.net · Oct 26, 2025

Biotech Stocks To Add to Your Watchlist – October 24th

Neuphoria Therapeutics, Danaher, and Qualigen Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that apply biological science and technology to develop drugs, therapies, diagnostics, vaccines, and related medical technologies. For investors they tend to be R&D‑intensive and highly dependent on clinical trial

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By